US Patent

US7820657 — Imidazolothiazole compounds for the treatment of disease

Composition of Matter · Assigned to Ambit Bioscience Corp · Expires 2028-09-26 · 2y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects imidazolothiazole compounds, including quizartinib dihydrochloride, for modulating receptor kinase activity and treating diseases mediated by receptor kinases.

USPTO Abstract

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: US7820657
Jurisdiction: US
Classification: Composition of Matter
Expires: 2028-09-26
Drug substance claim: Yes
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.